RMTG (Regenerative Medical Technology Group) 3-Year EBITDA Growth Rate: 56.10% (As of Jun. 2026) — 290% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerative Medical Technology Group 3-Year EBITDA Growth Rate?

Regenerative Medical Technology Group RMTG +5.28% 3-Year EBITDA Growth Rate is 56.10% as of Jun. 2026, which is 290% above its 10-year median of 14.40. The stock has 3 warning signs investors should review. Among 1,122 Biotechnology companies, Regenerative Medical Technology Group ranks better than 88.86% on this metric.

Regenerative Medical Technology Group's EBITDA per Share for the three months ended in Jun. 2026 was $-0.04.

During the past 12 months, Regenerative Medical Technology Group's average EBITDA Per Share Growth Rate was 120.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 56.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Regenerative Medical Technology Group was 56.10% per year. The lowest was -33.00% per year. And the median was 14.40% per year.

Regenerative Medical Technology Group  (OTCPK:RMTG) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Regenerative Medical Technology Group 3-Year EBITDA Growth Rate Related Terms

RMTG vs BZYR, CLSDQ, CDT: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Regenerative Medical Technology Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerative Medical Technology Group 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Regenerative Medical Technology Group's 3-Year EBITDA Growth Rate falls into.


Regenerative Medical Technology Group 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 56.10% mean?
Regenerative Medical Technology Group (RMTG) has a 3-Year EBITDA Growth Rate of 56.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regenerative Medical Technology Group and its competitors. This is 290% above median its historical median of 14.40. According to the industry distribution chart, Regenerative Medical Technology Group ranks #125 out of 1122 companies in the Biotechnology industry, placing it in the top 11.1%.
Is Regenerative Medical Technology Group's 3-Year EBITDA Growth Rate too high?
Regenerative Medical Technology Group's current 3-Year EBITDA Growth Rate of 56.10% is 290% above median its 10-year median of 14.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.75. Regenerative Medical Technology Group's value of 56.10% is 280.3% above this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #125 out of 1122 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Regenerative Medical Technology Group's 3-Year EBITDA Growth Rate compare to BZYR and CLSDQ?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #125 out of 1122 companies for 3-Year EBITDA Growth Rate. This places Regenerative Medical Technology Group in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.75. Regenerative Medical Technology Group's value of 56.10% is 280.3% above this benchmark. While the company's 10-year median is 14.40 vs. the industry median of 14.75, Regenerative Medical Technology Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.75, based on 1,122 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current 3-Year EBITDA Growth Rate of 56.10% is 280.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regenerative Medical Technology Group and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current 3-Year EBITDA Growth Rate is 56.10%, which is 290% above median its own 10-year median of 14.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Fairly Valued. The stock's GF Value™ is $0.08, compared to a current price of $0.08 — trading 1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 56.10%, which is 290% above median its 10-year median of 14.40 and 280.3% above the Biotechnology industry median of 14.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current 3-Year EBITDA Growth Rate is 56.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerative Medical Technology Group Business Description

Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.